Stony Brook Company Claims Its Prostate Cancer Test Superior PSA

A clinical trial found that a new system can more accurately show correlation between improvement and worsening of prostate cancer, according to the company.

prostate cancer

A test used in a clinical trial more directly correlates with prostate cancer progress and worsening than PSA, according to a Stony Brook-based company.

A Stony Brook-based company says it has developed a system that in a  clinical  trial correlated more closely to identifying prostate cancer’s development and defeat than PSA tests.

LineaRx said its system in a Phase II trial seeking recurrent prostate cancer demonstrates “the number of circulating tumor cells correlates more directly” with the status of the disease.

LineaRx, Inc., a subsidiary of  Applied DNA Sciences, Inc, said its platform demonstrated “superior correlation over Prostate Specific Antigen or PSA” in an ongoing Phase II trial in recurrent prostate cancer.

“The concentration of invasive circulating tumor cells or iCTCs identified per milliliter of whole blood correlated more directly with disease status than PSA levels,” the company said.